Cargando…

Tenapanor Improves Long-Term Control of Hyperphosphatemia in Patients Receiving Maintenance Dialysis: the NORMALIZE Study

KEY POINTS: Tenapanor is a first-in-class, minimally systemic sodium–hydrogen exchanger 3 inhibitor with a mechanism of action distinct from phosphate binders. Tenapanor alone or with phosphate binders led to 35%–49% of patients achieving serum phosphate ≤4.5 mg/dl over an 18-month period versus 22%...

Descripción completa

Detalles Bibliográficos
Autores principales:	Silva, Arnold L., Chertow, Glenn M., Hernandez, German T., Lynn, Robert I., Tietjen, David P., Rosenbaum, David P., Yang, Yang, Edelstein, Susan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Nephrology 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10695649/ https://www.ncbi.nlm.nih.gov/pubmed/37853560 http://dx.doi.org/10.34067/KID.0000000000000280

Ejemplares similares

The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia
por: Block, Geoffrey A, et al.
Publicado: (2019)

Tenapanor as Add-on Treatment for Hyperphosphatemia in Dialysis Patients: Enough Bang for the Buck?
por: Wish, Jay B.
Publicado: (2023)

Randomized Study of Tenapanor Added to Phosphate Binders for Patients With Refractory Hyperphosphatemia
por: Nitta, Kosaku, et al.
Publicado: (2023)

Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial
por: Inaba, Masaaki, et al.
Publicado: (2021)

Letter Regarding “Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial”
por: Aoki, Yuki, et al.
Publicado: (2022)

In Reply to “Letter Regarding ‘Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial’”
por: Inaba, Masaaki, et al.
Publicado: (2022)

Effect of Food Intake on the Pharmacodynamics of Tenapanor: A Phase 1 Study
por: Johansson, Susanne A., et al.
Publicado: (2017)

Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia
por: Koiwa, Fumihiko, et al.
Publicado: (2023)

Effects of Tenapanor on Cytochrome P450‐Mediated Drug‐Drug Interactions
por: Johansson, Susanne, et al.
Publicado: (2017)

Pharmacodynamics, Safety, and Tolerability of the NHE3 Inhibitor Tenapanor: Two Trials in Healthy Volunteers
por: Rosenbaum, David P., et al.
Publicado: (2018)

Risk factors for pulmonary hypertension in patients receiving maintenance peritoneal dialysis
por: Zeng, Y., et al.
Publicado: (2016)

Progression of Vascular Calcification and Clinical Outcomes in Patients Receiving Maintenance Dialysis
por: Zhang, Haitao, et al.
Publicado: (2023)

Tenapanor administration and the activity of the H(+)‐coupled transporter PepT1 in healthy volunteers
por: Johansson, Susanne, et al.
Publicado: (2017)

A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers
por: Johansson, Susanne, et al.
Publicado: (2016)

Control of hyperphosphatemia and maintenance of calcemia in CKD
por: Carvalho, Aluizio Barbosa, et al.
Publicado: (2021)

Use of Nicotinamide to Treat Hyperphosphatemia in Dialysis Patients
por: Lenglet, Aurélie, et al.
Publicado: (2013)

Prevalence and Correlates of Preference-Concordant Care Among Hospitalized People Receiving Maintenance Dialysis
por: Kazi, Basil S., et al.
Publicado: (2023)

Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2)
por: Chey, William D., et al.
Publicado: (2021)

Preclinical and Healthy Volunteer Studies of Potential Drug–Drug Interactions Between Tenapanor and Phosphate Binders
por: Johansson, Susanne, et al.
Publicado: (2016)

Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial
por: Chey, William D, et al.
Publicado: (2017)

SARS-CoV-2 Vaccine Effectiveness and Breakthrough Infections Among Patients Receiving Maintenance Dialysis
por: Manley, Harold J., et al.
Publicado: (2023)

Net Budgetary Impact of Ferric Citrate as a First-Line Phosphate Binder for the Treatment of Hyperphosphatemia: A Markov Microsimulation Model
por: Brunelli, Steven M., et al.
Publicado: (2017)

Thienopyridine Use After Coronary Stenting in Low Income Patients Enrolled in Medicare Part D Receiving Maintenance Dialysis
por: Chang, Tara I., et al.
Publicado: (2014)

Estimated SARS-CoV-2 Seroprevalence in US Patients Receiving Dialysis 1 Year After the Beginning of the COVID-19 Pandemic
por: Anand, Shuchi, et al.
Publicado: (2021)

Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1)
por: Chey, William D., et al.
Publicado: (2020)

Niacin as a drug repositioning candidate for hyperphosphatemia management in dialysis patients
por: Shin, Sooyoung, et al.
Publicado: (2014)

A Dialysis Patient With Hyperphosphatemia, Hyperkalemia, and Azotemia Without an Excessive Intake
por: Fukuoka, Kazuhito, et al.
Publicado: (2017)

Nicotinic acid and related compounds: A meta-analysis of their use for hyperphosphatemia in dialysis patients
por: Liu, Xianhua, et al.
Publicado: (2018)

Association of Hospitalization and Mortality Among Patients Initiating Dialysis With Hemodialysis Facility Ownership and Acquisitions
por: Erickson, Kevin F., et al.
Publicado: (2019)

Effect of Tenapanor on Phosphate Binder Pill Burden in Hemodialysis Patients
por: Akizawa, Tadao, et al.
Publicado: (2021)

Hyperphosphatemia and hs-CRP Initiate the Coronary Artery Calcification in Peritoneal Dialysis Patients
por: Shang, Da, et al.
Publicado: (2017)

Diabetes Mellitus and Younger Age Are Risk Factors for Hyperphosphatemia in Peritoneal Dialysis Patients
por: Imtiaz, Rameez, et al.
Publicado: (2017)

Cardiopulmonary Resuscitation Preferences of People Receiving Dialysis
por: Bernacki, Gwen M., et al.
Publicado: (2020)

Value Placed on Comfort vs Life Prolongation Among Patients Treated With Maintenance Dialysis
por: Wong, Susan P. Y., et al.
Publicado: (2023)

Intensified treatment of hyperphosphatemia associated with reduction in parathyroid hormone in patients on maintenance hemodialysis
por: Chen, Lan, et al.
Publicado: (2018)

Hyperphosphatemia as an independent risk factor for coronary artery calcification progression in peritoneal dialysis patients
por: Shang, Da, et al.
Publicado: (2015)

Association of Statin Therapy With Major Adverse Cardiovascular and Limb Outcomes in Patients With End-stage Kidney Disease and Peripheral Artery Disease Receiving Maintenance Dialysis
por: Lo, Hao-Yun, et al.
Publicado: (2022)

Unstable Housing and Mortality Among US Veterans Receiving Dialysis
por: Novick, Tessa K., et al.
Publicado: (2023)

Hyperphosphatemia is a combined function of high serum PTH and high dietary protein intake in dialysis patients
por: Streja, Elani, et al.
Publicado: (2013)

Hyperphosphatemia and Cardiovascular Disease
por: Zhou, Chao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v6rap56kgio7cs4608c2nmghpr